InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Meyer Colin John, Directeur de la Recherche. Director active across 1 company, notably Reata Pharmaceuticals INC. Aggregated, 12 reports have been logged. Breakdown: 0 buy · 3 sells. Total volume traded: €730k. History available since 3 January 2022. The latest transaction was filed on 15 August 2023 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
81,633 sharesClass A common stockSEC:0000899243-23-019538:0
2,144 shares@ US$169.068745.5% of flowClass A common stockSEC:0001209191-23-046294:0
6,000 shares0Class A common stockSEC:0001209191-23-041929:0
4,469 shares@ US$84.756847.7% of flowClass A common stockSEC:0001209191-23-030211:0
621 shares@ US$84.576.7% of flowClass A common stockSEC:0001209191-23-017240:0
88,636 sharesClass A common stockSEC:0001209191-23-016380:0
15,000 shares0Class A common stockSEC:0001209191-23-014102:0
23,513 shares0Class A common stockSEC:0001209191-23-001057:0
35,000 shares0Class A common stockSEC:0001209191-22-001635
35,000 shares0Class A common stockSEC:0001209191-22-001635:0
5,000 sharesClass A common stockSEC:0001209191-21-040884
5,000 sharesClass A common stockSEC:0001209191-21-040884:0
12 of 12 declarations
About Meyer Colin John
Colin John Meyer serves as Chief Research Officer at REATA PHARMACEUTICALS INC. He is responsible for leading the company's research and development efforts, contributing to innovation and advancement in pharmaceutical projects. His scientific expertise is essential for the company's success.
